JERUSALEM, ISRAEL – Hadassah Medical Organization announces that Amir Dagan, a healthcare executive with more than 20 years’ experience, has been named CEO of its innovation, entrepreneurship and commercialization company. Called Hadasit, the Jerusalem-based company generates average annual revenues of more than $13 million (roughly 50 million ILS) and has a portfolio of more than 250 active patent families in therapeutics, diagnostics and medical devices.
Before joining Hadasit, Dagan was CEO of Tissue Dynamics, an AI-driven drug development company collaborating with industry leaders Nvidia and Novo Nordisk, and Enopace Biomedical, which, in partnership with LivaNova, is developing a miniature electrical implant for treating heart failure. Earlier in his career, Dagan was a member of the life sciences investment team at Evergreen Venture Capital, where he specialized in funding and scaling up new healthcare ventures.
Founded in 1986 and Israel’s first technology transfer company, Hadasit (Hebrew and pronounced “hah-dah-SEAT”) was created to bring life-saving medical technologies and products to market. The company derives its more than $13 million in annual revenues from the applied research activities of Hadassah Medical Organization’s physicians and scientists. Each year, the company submits dozens of new patent applications, establishes myriad startup companies and collaborates with industry in various areas, including technology development and validation, access to medical data and R&D services.
As CEO of Hadasit, Dagan will drive Hadassah Medical Organization’s innovation strategy, focusing on commercializing medical technologies, fostering partnerships with industry leaders and launching biomedical startups. His responsibilities will include establishing an innovation and business development center; managing Hadasit’s software accelerator, which provides access to real-world data as well as clinicians and patients in collaboration with IBM; and promoting Hadasit’s JumpStart Program, which helps propel medical technology ventures.
Dagan will also lead Hadassah Medical Organization’s effort to create a dedicated investment fund to support startups based on Hadassah researchers’ patents.
Hadassah Medical Organization, also known as Hadassah Medical Center, was founded and is owned by Hadassah, The Women’s Zionist Organization of America.
About Hadasit:
Founded in 1986 and Israel’s first technology transfer venture, Hadasit is the innovation, entrepreneurship and commercialization company of Hadassah Medical Organization (also known as Hadassah Medical Center). Created to bring life-saving medical technologies and products to market by leveraging the research and clinical experience of Hadassah’s physicians and scientists, Hadasit has average annual revenues of more than $13 million and a portfolio of more than 250 active patent families covering a wide variety of therapeutics, diagnostics and medical devices. In harnessing new business, innovation and collaboration models, Hadasit is creating synergies among academia, industry and medicine that are changing the face of healthcare across the globe. For more information, visit hadasit.org.il/.
About Hadassah Medical Organization:
For more than a century, Hadassah Medical Organization, the Jerusalem-based hospital system founded and owned by Hadassah, The Women’s Zionist Organization of America, has set the standard for excellence in medical treatment and research in Israel. The experience and ingenuity of Hadassah’s doctors and scientists have led to new tools and treatments in all areas of medicine, including therapeutics, diagnostics and medical devices. For more information, visit hadassah.org/how-we-help/our-hospitals.